Last reviewed · How we verify

Cardiovascular disease — Treatment Landscape & Competitive Intelligence

Cardiovascular disease (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cardiovascular disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Repatha EVOLOCUMAB Repatha PCSK9 Inhibitor [EPC] PCSK9 2015-01-01
Colcrys COLCHICINE Scilex Pharms Alkaloid [EPC] Serine/threonine-protein kinase pim-1 1961-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Repatha · 1 drug in Cardiovascular disease
  2. Scilex Pharms · 1 drug in Cardiovascular disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cardiovascular disease:

Cite this brief

Drug Landscape (2026). Cardiovascular disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cardiovascular-disease. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing